Loading
A phase 2 trial of Busulfan, Gemcitabine, Melphalan and Panobinostat in Plasma cell leukaemia, run by M.D. Anderson Cancer Center, completed.
Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma is a phase 2 interventional study registered as NCT02506959 by M.D. Anderson Cancer Center, with 83 participants recorded, started 2015-09-14 and reaching its primary completion in 2024-06-03. Interventions recorded: Autologous Hematopoietic Stem Cell Transplantation, Busulfan, Gemcitabine Hydrochloride, Melphalan, Panobinostat, Peripheral Blood Stem Cell Transplantation, Pharmacological Study. Conditions recorded: Plasma Cell Leukemia, Plasmacytoma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma.
Linked to the drug Panobinostat because the registry names it among its interventions and Plasma cell leukaemia among its conditions. Registry record only: no result has been read by an editor.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
83 enrolled.
Figures from the ClinicalTrials.gov results section (first posted 2025-03-18), not from a publication
SourceFigures from the ClinicalTrials.gov results section (first posted 2025-03-18), not from a publication
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression Free Survival (PFS)primary | Cohort 1_1st Auto TP Conditioned With Panobinostat and Gem/Bu/Mel | 50 | 38 participants | - | - | link |
| Cohort 2_2nd Auto TP Conditioned With Panobinostat and Gem/Bu/Mel | 33 | 24 participants | ||||
| Overall Survival (OS) | Cohort 1_1st Auto TP Conditioned With Panobinostat and Gem/Bu/Mel | 50 | 27 participants | - | - | link |
| Cohort 2_2nd Auto TP Conditioned With Panobinostat and Gem/Bu/Mel | 33 | 16 participants |
Shares Panobinostat and the tag pipeline.
Shares Panobinostat and the tag pipeline.
Shares Busulfan and the tag pipeline.
Shares Busulfan, Melphalan (including hepatic delivery system) and the tag pipeline.
Shares Melphalan (including hepatic delivery system) and the tag pipeline.
Shares Busulfan and the tag pipeline.
Shares Panobinostat, Gemcitabine and the tag pipeline.
Shares Gemcitabine and the tag pipeline.